Stem Cell Assay

Stem Cell Assay

Global Stem Cell Assay Market to Reach $3.4 Billion by 2027

Amid the COVID-19 crisis, the global market for Stem Cell Assay estimated at US$932.2 Million in the year 2020, is projected to reach a revised size of US$3.4 Billion by 2027, growing at a CAGR of 20.1% over the analysis period 2020-2027. Viability/Cytotoxicity, one of the segments analyzed in the report, is projected to record a 22.4% CAGR and reach US$1.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Isolation & Purification segment is readjusted to a revised 18.7% CAGR for the next 7-year period.

The U.S. Market is Estimated at $276.8 Million, While China is Forecast to Grow at 19.2% CAGR

The Stem Cell Assay market in the U.S. is estimated at US$276.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$570.5 Million by the year 2027 trailing a CAGR of 19.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18% and 17.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.

Cell Identification Segment to Record 20.3% CAGR

In the global Cell Identification segment, USA, Canada, Japan, China and Europe will drive the 20.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$85.6 Million in the year 2020 will reach a projected size of US$308.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$404.3 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 244-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

• Bio-Rad Laboratories, Inc.
• Bio-Techne Corporation
• Cell Biolabs, Inc.
• Cellular Dynamics International
• GE Healthcare
• HemoGenix, Inc.
• Merck & Co., Inc.
• Miltenyi Biotec GmbH
• PerkinElmer, Inc.
• Promega Corporation
• Stemcell Technologies Canada, Inc.
• Thermo Fisher Scientific, Inc.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.